Skip to main content
Caplight Logo









GEMMA Biotherapeutics

GEMMA Biotherapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.gemmabiotx.com/

Last Round

Grant

Jul 9, 2026

Total Funding Raised

$34M

Company Overview

GEMMA Biotherapeutics is a biotechnology company that develops gene therapies for rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Revenue Share

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVrare diseasebiotechnologygenetic medicinebiotech startupdrug discoveryclinical stagetherapeutic pipelineprecision medicinedelivery platformbiopharmaclinical trialsintellectual property

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GEMMA Biotherapeutics Comparables

Compare GEMMA Biotherapeutics with similar companies based on industry and business-model similarity.

GEMMA Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iECURE
81%
Capsida Biotherapeutics
81%
Passage Bio
79%

GEMMA Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 9, 2026
SeedDec 23, 2024
StrategicOct 8, 2024

Key People

Founding team and executive leadership

James M. Wilson

President And Chief Executive Officer

Executive Team

Lori D Kellam

Chief Operating Officer

Executive Team

Juliette Hordeaux

Chief Scientific Officer

Executive Team

Ramon S.

Chief Business Officer

Executive Team

GEMMA Biotherapeutics Investors

Notable investors and investment history

GEMMA Biotherapeutics investors
InvestorRounds
Bioluminescence VenturesSeed
ARPA-HGrant
Earlybird Venture CapitalSeed
Double Point VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Affiliation with Franklin Biolabs to translate scientific work into clinical trials.

  • Mar 1, 2026

    Gene therapy pioneer Jim Wilson appointed to lead the company.

GEMMA Biotherapeutics Filings

Explore SEC and related filing metadata, where available.

GEMMA Biotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GEMMA Biotherapeutics's valuation, stock price, and market status.

Is GEMMA Biotherapeutics a public or private company?

GEMMA Biotherapeutics is a private company.

What is the current stock price of GEMMA Biotherapeutics?

GEMMA Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is GEMMA Biotherapeutics worth (valuation)?

Valuation information for GEMMA Biotherapeutics is not publicly available.

Can I buy GEMMA Biotherapeutics stock?

GEMMA Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GEMMA Biotherapeutics's last funding round?

GEMMA Biotherapeutics's most recent funding round was Seed on December 23, 2024.

Who are the main investors in GEMMA Biotherapeutics?

Key investors in GEMMA Biotherapeutics include Bioluminescence Ventures, Earlybird Venture Capital, Double Point Ventures.

Will GEMMA Biotherapeutics IPO soon?

No public IPO plans have been announced for GEMMA Biotherapeutics.

How can I track GEMMA Biotherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GEMMA Biotherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range66
Year Founded2024
Last FundingJul 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?